Boston sweeps up Bayer’s interventional devices
This article was originally published in Clinica
Executive Summary
Bayer HealthCare is casting off its interventional device unit, Medrad, and selling it to Boston Scientific for an agreed $415m in cash. The total consideration includes fees for transitional services.